Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» DF6002
DF6002
BMS returns $475M IL-12 oncology asset to Dragonfly’s pond
Fierce Biotech
Mon, 02/6/23 - 06:12 pm
Dragonfly Therapeutics
Bristol Myers Squibb
oncology
DF6002
solid tumors
Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program
Fierce Biotech
Mon, 08/17/20 - 10:34 am
Bristol-Myers Squibb
Dragonfly Therapeutics
IL-12 immunotherapy
DF6002